Immune Profiles in Myasthenia Gravis

Summary

The investigators aim to better describe the immune profile in myasthenia gravis (MG), including lymphocyte subset, cytokine and complement profiles; how they differ between patients of different severity, at times of disease exacerbation, and with different immunosuppressive treatments. The investigators hope to build a clearer picture of how different immune measures vary in MG, contributing to the understanding of the patho\[physiology of the disease, and working towards a biomarker that might help clinicians optimise an individual's treatment.

the investigators aim to take into account the heterogeneity of MG by taking into account age of onset of MG (early vs late onset) and focussing on acetylcholine receptor antibody (AChR) positive, non-thymomatous MG aged 18-80.

Conditions

• Myasthenia Gravis

Sponsors & Collaborators

• Northern Care Alliance NHS Foundation Trust

  collaborator OTHER

• Walton Centre NHS Foundation Trust

  collaborator OTHER

• Oxford University Hospitals NHS Trust

  collaborator OTHER

• University College London Hospitals

  collaborator OTHER

• University Hospital Birmingham NHS Foundation Trust

  collaborator OTHER

• Imperial College Healthcare NHS Trust

  collaborator OTHER

• Newcastle-upon-Tyne Hospitals NHS Trust

  collaborator OTHER

• King's College Hospital NHS Trust

  collaborator OTHER

• Nottingham University Hospitals NHS Trust

  collaborator OTHER

• University Hospital Southampton NHS Foundation Trust

  collaborator OTHER

• Cardiff University

  collaborator OTHER

• University of Manchester

  lead OTHER

Principal Investigators

• Katherine Dodd, MBChB MRCP · University of Manchester

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2021-10-31

Primary Completion

2024-04-30

Completion

2024-04-30